Skip to main content
. 2021 Jun 10;11:648809. doi: 10.3389/fonc.2021.648809

Figure 6.

Figure 6

Ipriflavone inhibits ESCC patient‐derived tumor growth in vivo. Mice were divided into two groups for assessing the effect of Ipriflavone on ESCC PDX tumor growth. Groups are as follows: 1) vehicle group or 2) group treated with 100 mg/kg of Ipriflavone. Tumor-bearing mice were orally administered (by gavage) Ipriflavone or vehicle once a day Monday through Friday for 62 days. Tumor volumes were measured on the days indicated. (A) The effect of Ipriflavone on ESCC tumor growth. (B) Effect of Ipriflavone on Ki‐67 expression. Vehicle and Ipriflavone groups of tumor tissues were stained with Ki‐67 antibody (×40, ×100 magnification, left panel). The number of Ki‐67‐stained cells was counted from immunohistochemistry results (n = 6; * P < 0.05) (right panel). (C) Effect of Ipriflavone on the mTOR signaling pathway. Vehicle and Ipriflavone groups of tumor tissues were analyzed by Western blotting. (D) Effect of Ipriflavone on mouse body weight. Body weights of mice were obtained once a week. Data are shown as means ± S.E. of values obtained from the experiments. (E) Effect of Ipriflavone on ALT and AST activity. Before sacrifice mice, blood from vehicle and Ipriflavone groups were collected and analyzed. All data are shown as means ± S.E. of values obtained from the experiment groups. The asterisk (*) indicates a significant difference between tumors from vehicle-treated group or Ipriflavone-treated group mice as determined by t test (p < 0.05).